Kawasaki disease is not curable in the traditional sense, but it is highly treatable, and the vast majority of children recover fully. The illness runs a self-limited course, meaning it resolves on its own over several weeks. The real goal of treatment is not to “cure” the disease itself but to prevent it from damaging the coronary arteries, which supply blood to the heart. When treated within the first 10 days of fever, the risk of developing coronary artery problems drops from as high as 25% to roughly 2% to 3%.
What Kawasaki Disease Does to the Body
Kawasaki disease causes widespread inflammation of blood vessels throughout the body, primarily in young children. It remains a clinical diagnosis, meaning there is no single lab test that confirms it. Doctors look for a combination of signs: persistent high fever (typically 39°C to 40.5°C), rash, red eyes without discharge, swollen or red hands and feet, swollen lymph nodes on one side of the neck, and changes in the lips and tongue, including what’s called “strawberry tongue.” These symptoms usually appear over two to five days after fever begins.
The disease moves through three distinct phases. The acute phase starts with the onset of fever and lasts about 10 to 14 days without treatment. The subacute phase begins when the fever breaks and continues until symptoms resolve, generally between day 10 and day 25. The convalescent phase follows, lasting until blood markers return to normal, typically 25 days to two months after the fever first appeared. Even without any treatment, the visible symptoms eventually go away on their own. The danger is what happens silently during those weeks: inflammation can weaken and stretch the walls of the coronary arteries, forming balloon-like bulges called aneurysms.
How Treatment Works
The standard treatment combines two components: a single high-dose infusion of immunoglobulin (a concentrated solution of antibodies given through an IV) and aspirin. Treatment is most effective when started within the first 10 days of illness, and ideally around day 5. The immunoglobulin infusion is given over 24 hours and works by calming the immune system’s inflammatory response before it can damage the coronary arteries.
During the acute phase, children receive a higher dose of aspirin to help control inflammation and fever. Once the fever has been gone for about 48 hours, the aspirin dose is lowered to a smaller amount that helps prevent blood clots. This low-dose aspirin continues for four to six weeks, or longer if there are signs of coronary artery changes.
For most children, this single round of treatment is enough. The fever typically breaks within 36 hours, and the other symptoms gradually fade over the following weeks.
When Initial Treatment Doesn’t Work
Roughly 10% to 20% of children don’t respond to the first round of immunoglobulin, meaning their fever returns or persists. These cases are considered “refractory,” and doctors have several options. The most common approaches include a second immunoglobulin infusion, corticosteroids to suppress inflammation more aggressively, or a biologic medication called infliximab that blocks a specific inflammatory protein.
There is ongoing debate among specialists about which second-line treatment works best. A large U.S. trial published in The Lancet found that infliximab performed comparably to a second immunoglobulin infusion for refractory cases, challenging older guidelines that favored repeating the immunoglobulin. In Japan, researchers have developed scoring systems to predict which children are likely to be resistant to initial treatment, allowing doctors to add corticosteroids from the start for high-risk patients.
Long-Term Outlook for Most Children
Children who receive timely treatment and show no coronary artery changes have an excellent prognosis. Their blood vessels heal, their lab values normalize, and they go on to live without restrictions. For these children, Kawasaki disease is essentially a one-time event with full recovery.
Recurrence is uncommon. About 2% of children experience a second episode, and when it does happen, it usually occurs within the first year after the original illness.
After recovery, children without coronary complications typically need a follow-up echocardiogram (an ultrasound of the heart) several weeks after the illness to confirm the coronary arteries look normal. If everything checks out, most do not require ongoing cardiac monitoring, though recommendations vary by physician.
When Coronary Arteries Are Affected
The picture is more complex for the small percentage of children who develop coronary artery aneurysms. In untreated Kawasaki disease, 15% to 25% of children develop these aneurysms. With treatment, that number falls to 2% to 3%, but it doesn’t reach zero.
Smaller aneurysms often resolve on their own within one to two years as the artery walls heal and remodel. Larger aneurysms (6 mm or greater in diameter) are more concerning. A long-term study following children with large aneurysms over an average of 12.5 years found a cumulative survival rate of 89.6%. About 28% of those patients needed catheter-based or surgical procedures during the follow-up period. Most heart attacks in this group occurred within the first year after the aneurysms formed, making that early window the highest-risk period.
Children with persistent aneurysms need lifelong cardiovascular monitoring. This includes periodic imaging to check for narrowing of the coronary arteries, blood-thinning medications to prevent clots from forming inside the aneurysms, and activity guidelines tailored to the severity of their condition. Advances in cardiovascular imaging have improved the ability to detect narrowing and blood flow problems in these patients, though questions remain about how often imaging should be repeated and which techniques are most reliable for spotting early warning signs.
What “Curable” Really Means Here
Kawasaki disease does not become a chronic condition in the way that asthma or diabetes does. The acute illness resolves, and for the large majority of children, it leaves no lasting trace. In that practical sense, yes, most children are cured. But the word “curable” implies that treatment eliminates the disease, and that’s not quite what happens. Treatment controls the inflammation and prevents complications. The disease itself runs its course regardless.
The critical variable is timing. Children diagnosed and treated early have outcomes that are, for all practical purposes, indistinguishable from never having had the disease. Children diagnosed late, or those in the small group who develop significant coronary damage despite treatment, face a longer road that may include ongoing medication, imaging, and in some cases, interventional procedures. Even in that group, long-term survival is high, and medical management continues to improve.